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grams of sufentanyl just before epicardial access and that was repeated up to
4 times (20 μg) in case of persistent pain and absence of respiratory depres-
sion. Blood pressure and O2 saturation were continuously monitored.
Results: 74 epicardial VT ablations have been performed in 65 patients (58 M,
58±13yo), 58 (89%) had a structural heart disease with a mean LVEF of 40±15%.
69 were performed under conscious sedation using the above protocol. 5 proce-
dures were performed under GA: 4 because patients had to be sedated for
arrhythmic storm before ablation and 1because of respiratory contraindications.
Mean midazolam and sufentanyl dosages were 4±1,5 mg and 10±5 μg respec-
tively. RF ablation was performed in 57 procedures with mean epicardial RF dura-
tion of 9±11 min for a total procedure time of 243 ±90 min. Because of pericardial
bleeding 2 patients were transferred to the operating room and one patient had
developed metabolic acidosis but no patient had respiratory failure during the pro-
cedure.
Conclusion: Epicardial VT ablation can be performed safely under con-
scious sedation using powerful painkiller such as sufentanyl.
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Acute pericardial effusion following atrial fibrillation ablation: cha-
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Background: Pericardial effusion can occur during or after atrial fibrilla-
tion ablation and may induce atrial arrhythmia.
Aims: We aimed to characterize the impact of pericardial effusion on
arrhythmia recurrences following atrial fibrillation ablation.
Methods: We studied prospectively patients referred for a first atrial fibrilla-
tion ablation. We performed transthoracic echocardiography before and 24 hours
after the procedure. If pericardial effusion was present, transthoracic echocardio-
graphy was repeated at one month to evaluate pericardial effusion evolution. Early
arrhythmia recurrences were defined as any arrhythmia documented within
1 month following the procedure. Eighty-one patients were included in our study.
Results: Pericardial effusion was diagnosed in 22% of cases and was present
in 35% of patients with persistent atrial fibrillation vs. 10% for paroxysmal atrial
fibrillation (p=0.008). Pericardial effusions were mild (6±3 mm), asymptomatic
(89%) and none of them required pericardiocentesis.
Early and late arrhythmia recurrences were present in 31% and 36%
respectively in our population. The incidence of pericardial effusion was sig-
nificantly higher in patients with early arrhythmia recurrences compared to
patients without early arrhythmia recurrences (48% vs. 11%, p=0.0004). On
multivariate analysis pericardial effusion and duration in atrial fibrillation
were the two independent predictors of early arrhythmia recurrences.
Pericardial effusion incidence was similar in patients with and without late
arrhythmia recurrences. At one month none of our patients had PE on TTE.
Conclusion: Pericardial effusion following atrial fibrillation ablation is fre-
quent, particularly following persistent atrial fibrillation ablation. This effu-
sion is mild, mainly asymptomatic and independently associated with early
arrhythmia recurrences.
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Aims: We analysed outcomes of 163 patients (pts) with ICD using remote
monitoring follow-up (RFU)
Methods: 163 pts were implanted with an ICD with a Remote Patient
Management (RPM) system. 82 patients (51%) were implanted with biventric-
ular ICDs (CRT-D), 63 (39%) with dual chamber ICDs (D-ICD), and 15 (9%)
with single chamber ICDs (S-ICD). 31 CRT-D pts had also weight and blood
pressure monitoring. RFU was performed every 3 months.
Results: Mean FU with RPM system was 15±10 months. 379 episodes of sus-
tained atrial arrhythmias occured in 13 pts. 287 episodes of ventricular arrhyth-
mias required therapies: 265 (90.6%) were approprialely treated by Anti-
Tachycardia Pacing (ATP), 22 with ICD discharge,only 3 inappropriate shocks. In
the last 7 months of FU, 25 patients were examined at hospital after non-vital
alerts: oral anticoagulation(4 pts) and amiodarone(2 pts) were started, diuretics
dosage increased (5 pts),device reprogrammed in 14 patients. During FU,
5 patients had VT recurrences requiring VT ablation (2 pts),1 pt required a short
heart failure hospitalisation. Pts with S-ICD had less clinical FU in hospital. D-
ICD pts had a higher rate of RFU. In 13 CRT-D pts, alarms indicated biventricular
pacing <85%:we reprogrammed the device (2 pts), changed medical therapeutics
(5 pts), performed AV junction(5 pts) and cavo-tricuspid ablation (1 pt).
Conclusion: RPM is an effective tool for the FU of ICD pts. D-ICDs and
CRT-ICDs had more RPM alerts, and could early detect atrial arrythmias
comparing to S-ICD. RPM helps both physicians and pts for HF management
and for reducing inappropriate ICD shocks.
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Paroxysmal supraventricular tachycardia (SVT) requires a treatment in
patients with recurrent SVT’s. Some of them refuse the radical treatment of
SVT. The purpose of the study was to know the number of patients who
accept SVT ablation, the reasons and the delay between initial electrophysio-
logical study (EPS) and the time of ablation.
Methods: 1268 patients with a normal ECG in sinus rhythm were consec-
utively recruited for SVT’s, confirmed by EPS. Patients with anterograde con-
duction through an accessory pathway (AP) were excluded. Ablation
indications and the time between EPS and ablation were studied.
Results: 652 patients were directly seen for EPS and ablation, because SVT’s
were documented and recurrent (group I). SVT was induced at EPS in
481 patients, but ablation was not performed (group II). Ablation was performed
in a second time after EPS in 135 patients (group III). The mean time between
EPS and ablation was 4±5 years. Group I differs from group II and III by an older
age (53±18 vs 47±19 and 43±18.5 years, p<0.0000), the female gender more fre-
quent than in group II (64.5% vs 55%, p<0.001), but similar in group III (61%).
Syncope associated with SVT was less frequent in group I (7.5%) than in group II
(18/5%) and III (19%) (p<0.0000). The rate in tachycardia was slower in group I
(177±34 bpm) than in group II (189±38) (p<0.0005) and III (193±33) (p<0.0001).
The electrophysiological mechanism was similar in 3 groups. Reentry in a con-
cealed AP was noted in 17.5% of group I patients, 21% of group II patients and
19% of group II patients. Typical and atypical atrioventricular nodal reentrant
tachycardias represent the other causes.
Conclusions: Among patients with proved SVT at EPS, ablation of the
substrate will never be achieved in 38% of patients and will be made at least
4 years after the evaluation in 11% of patients. Only age and gender influence
the decision. Symptoms, rate and mechanism of SVT do not change the indi-
cations of ablation.
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Purpose: Increasing numbers of patients requiring arrhythmia device
implantation are treated with clopidogrel. This study aimed to assess the risk
